Sara Doolin-Thompson, APRN
Family · Philpot, KYNPI 1992281323
Payments from drug & device makers
Across 596 payments — averaging $52.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$22K
- Medtronic$4K
- Novo Nordisk$1K
- Boehringer Ingelheim$622
- Lilly USA, LLC$572
- Sanofi-aventis U.S. LLC$541
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,7005%
- Speaking & faculty fees$10,05032%
- Travel & lodging$8,61228%
- Food & beverage$10,73334%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 200 | $22,320 |
| Medtronic | 83 | $3,567 |
| Novo Nordisk | 78 | $1,030 |
| Boehringer Ingelheim | 31 | $622 |
| Lilly USA, LLC | 32 | $572 |
| Sanofi-aventis U.S. LLC | 22 | $541 |
| AstraZeneca | 29 | $514 |
| Bayer | 25 | $482 |
| Corcept Therapeutics | 28 | $384 |
| Abbott | 16 | $262 |
| Amgen | 13 | $258 |
| AbbVie | 8 | $147 |
| Insulet Corporation | 7 | $114 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Nevro Corp. | 3 | $55 |
| Tandem Diabetes Care, Inc. | 3 | $51 |
| Dexcom, Inc. | 2 | $42 |
| Merck | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Novartis | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Zealand Pharma US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$19,313
- INPEN SMART INSULIN DELIVERY SYSTEM$834
- MINIMED 780G$751
- InPen$356
- SOLIQUA 100/33$124
- JARDIANCE$121
How this compares
$31,233 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 312 | $334,144 |
| Xigduo XrDapaglifloz Propaned/Metformin | 186 | $182,704 |
| MounjaroTirzepatide | 138 | $164,634 |
| FarxigaDapagliflozin Propanediol | 144 | $130,314 |
| AfrezzaInsulin Regular, Human | 34 | $108,792 |
| KerendiaFinerenone | 73 | $84,370 |
| OtezlaApremilast | 11 | $58,248 |
| JardianceEmpagliflozin | 48 | $42,815 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 58 | $42,176 |
| RybelsusSemaglutide | 24 | $35,139 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $35,006 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $30,450 |
| TrulicityDulaglutide | 13 | $20,927 |
| Praluent PenAlirocumab | 41 | $19,623 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $18,979 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,030 | $369,283336 claims |
| Lilly USA, LLCMounjaro, Trulicity | $572 | $185,561151 claims |
| AstraZenecaFarxiga | $514 | $130,314144 claims |
| Mannkind CorporationAfrezza | $22,320 | $108,79234 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $622 | $84,991106 claims |
| BayerKerendia | $482 | $84,37073 claims |
| AmgenOtezla | $258 | $58,24811 claims |
| AbbVieSynthroid | $147 | $4,26373 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Philpot
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.